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Abstract
Aims: Somatic symptomatology is common in depression, and is often attributed to the Freudian-
inspired concept of "somatization". While the same somatic symptoms and depression are
common in mitochondrial disease, in cases with concurrent mood symptoms the diagnosis of a
mitochondrial disorder and related therapy are typically delayed for many years. A short screening
tool that can identify patients with depression at high risk for having underlying mitochondrial
dysfunction is presented.
Methods: Six items of the Karolinska Scales of Personality (KSP) were found to differentiate
among 21 chronically-depressed Swedish subjects with low versus normal muscle ATP production
rates. A screening tool consisting of the six KSP questions was validated in the relatives of American
genetics clinic patients, including in 24 matrilineal relatives in families with maternally inherited
mitochondrial disease and in 30 control relatives.
Results: Among the depressed Swedish patients, the screening tool was positive in 13/14 with low
and 1/7 with normal mitochondrial function (P = 0.0003). Applied to the American relatives of
patients, the screening tool was positive in 13/24 matrilineal relatives and in 1/30 control relatives
(P = 2 × 10-5).
Conclusion:  Our preliminary data suggest that a small number of specific somatic-related
questions can be constructed into a valid screening tool for cases at high risk for having a
component of energy metabolism in their pathogenesis.
Findings
Multiple medically-unexplained somatic complaints, usu-
ally associated with mood symptoms, is currently desig-
nated as "somatization" under the Diagnostic and
Statistical Manual (DSM) system used to classify mental
illness. This phenomenon has been observed by physi-
cians for at least 3000 years and was known as "hysteria"
until the previous DSM designation of "Briquet's syn-
drome". The French physician Briquet, in his 1859 treatise
on hysteria, described mood as well as a long list of
somatic symptoms among his 430 patients, including
migraine, abdominal pain, muscle pain, palpitations,
restlessness, hyperesthesias, anesthesias and fatigue [1].
While Briquet assumed that his patients' symptomatology
had a biological basis, many mental health providers
today practice under the assumption that prominent
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somatic symptomology among depressed individuals are
of psychic origin, a theory often attributed to the work of
Sigmund Freud.
However, in 1895, Freud and Breuer in their classical
study of hysteria [2] actually postulated the presence of
underlying genetic-biological factors in their patients as
exemplified by the comments by Freud " [she] was
undoubtedly a person with a severe neuropathic heredity.
To accomplish hysteria without a disposition of this kind
would most likely be impossible" (page 93), and
"...somatic pain was not created by the neurosis, but sim-
ply used, heightened and maintained by it" (page 177).
The popular concept of the symbolic conversion of psy-
chic conflicts into somatic symptoms by the unconscious
mind was presented by Freud and Breuer in order to
explain the specific somatic manifestations reported, not
necessarily their initial pathogenesis.
Unfortunately, considering the high prevalence and asso-
ciated disability of depression with somatization, there
has been little advancement in our understanding of its
pathogenesis since the time of Freud. As the same somatic
and mood symptoms are common in patients with mito-
chondrial disorders [3-8], recently-described genetic con-
ditions that result from a decreased production of
adenosine triphosphate (ATP, cellular energy), we have
hypothesized that a relative cellular energy depletion can
serve as an important risk factor predisposing some indi-
viduals towards the development of both somatic symp-
tomatology and depression [9].
There is substantial overlap between patients identified
with somatization and with mitochondrial disorders. In
the latter conditions, symptoms typically wax and wane,
and involve different tissues and body locations at differ-
ent times, presumably in accordance with local energy
supply and demand. These and other factors often lead
the patient's symptoms to be dismissed as being "func-
tional" or "psychosomatic", delaying typically by many
years the specific testing that establishes the diagnosis of a
mitochondrial disorder in patients with concurrent mood
symptoms [4,8].
Recently, we reported on in vitro muscle ATP production
rates using α-ketoglutarate as substrate in 21 adult Swed-
ish subjects with longstanding major depression [10].
Consistent with previous findings [11], almost one-half of
our chronically-depressed subjects exhibited very high
levels of somatic complaints on self-reported scales indi-
cating somatization. Essentially every one of those "soma-
tizing" depressed subjects demonstrated a muscle ATP
production rate below that measured in 10 healthy con-
trols [10]. However, while supporting our hypothesis
regarding a mitochondrial component in the pathogene-
sis of depression with somatization, our findings are of
limited immediate clinical utility since the modalities that
were used were 30 items from the Karolinska Scales of Per-
sonality (KSP) and an open muscle biopsy.
Inspired by the World Health Organization six-item, 5-
point response format, self-report scale for the screening
of adult Attention Deficit Hyperactivity Disorder (ADHD)
[12], we have herein taken the first steps towards the
development of a screening tool that rapidly can identify
those individuals that are most likely to have mitochon-
drial dysfunction, and hence most likely to benefit from
related therapies.
We re-evaluated our data [10] from the 21 adult subjects
from Sweden with longstanding major depression and
audiological disease (hearing loss or tinnitus) mentioned
above in terms of the responses to individual KSP items in
subjects with low versus  with normal ATP production
rates.
In order to validate our screening instrument, English
translations [13] of the six KSP items with the highest
degrees of association with mitochondrial function in the
above group were added to a larger five-page question-
naire that was self-completed by a second set of subjects.
Mothers were recruited from the Genetics clinics at Child-
rens Hospital Los Angeles; mothers of mitochondrial
patients were asked to recruit specific relatives as well. The
"mitochondrial group" consisted of 24 subjects: 17 moth-
ers and 7 maternal aunts of patients with maternally
inherited mitochondrial disease. Since the mitochondrial
DNA (mtDNA) is maternally inherited intact from a
mother to all of her children without recombination or
paternal component, those relatives have the same
mtDNA sequence as the patients, and presumably some
degree of energy depletion. Mitochondrial disease was
defined by the established Nijmegen criteria (at the level
of "probable" or "definite") [14], and maternal inherit-
ance was defined by our quantitative pedigree analysis
method [15]. The "control group" consisted of 30 sub-
jects: 6 paternal aunts and 6 aunts-in-law (uncles' wives)
of the same families, thus having different mtDNA
sequences than our patients, as well as 18 mothers of
clinic patients with autosomal recessive metabolic disor-
ders.
Three of the 15 KSP scales, Somatic Anxiety, Muscular
Tension and Psychasthenia, inquire regarding somatic
symptomology or reactions to that symptomology
[10,13], and were the focus of this study. The KSP has four
possible choices for each item: "Applies Completely"
(score 4), "Applies Rather Well" (score 3), "Does Not
Apply Well" (score 2) and "Does Not Apply at All" (score
1). Since some degree of somatic symptoms are nearlyBioPsychoSocial Medicine 2008, 2:7 http://www.bpsmedicine.com/content/2/1/7
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universal, yet in our experience are highly exaggerated in
patients with mitochondrial disorders, we evaluated the
items based upon the maximum score of 4 ("Applies
Completely") versus all other scores.
Among the American relatives, the presence of "depres-
sion" was defined as a probable diagnosis of major
depressive disorder based upon meeting the DSM Ver-
sion-IV-TR criteria for that condition from questionnaire
data, or the relative had been given a diagnosis of "depres-
sion" and treated for such by a medical or mental health
professional.
In our 21 depressed subjects from Sweden, a score of 4
was found to be statistically more common (P < 0.05) in
10 of the 30 somatization-related KSP items [10] among
the subjects with low ATP production rates versus among
the subjects with normal ATP production rates. In con-
trast, a score of 4 was not found to be statistically more
common among subjects with normal ATP production
rates for any of the 30 items. For six of the 10 items (Table
1), a score of 4 was selected by at least eight of the 14 sub-
jects with low ATP production rates, and by no more than
one of the seven subjects with normal ATP production
rates. Thirteen of the 14 subjects with ATP production
rates below the normal range answered at least two of
those six items as "Applies Completely" (sensitivity =
93%), versus only 1 of 7 subjects with ATP production
rates within our control range (specificity = 86%, chi-
square P = 0.0003) (Figure 1).
In the American relatives of subjects, five of the six KSP
items listed in Table 1 were answered as "Applies Com-
pletely" statistically more often in the mitochondrial
group versus in the subjects in the control group (Table 1,
right-hand column). At least two of the six-KSP items
listed in Table 1 were answered as "Applies Completely"
in 13/24 of the mitochondrial group (10/17 mothers and
3/7 maternal aunts) and in 1/30 of the control group (0/
6 paternal aunts, 0/6 aunts-in-law and 1/18 mothers of
children with recessive disorders) (P = 2 × 10-5). This cor-
responds to 54% sensitivity and 97% specificity. Eleven of
the 24 (46%) relatives in the mitochondrial group had a
lifetime diagnosis of depression, versus 3 of 28 (11%)
control relatives (P = 2 × 10-5). There was no correlation
between the presence or absence of depression and the
KSP screening results.
Among our Swedish subjects with lower levels of mito-
chondrial function, the choice of the extreme "Applies
Completely" response may reflect either more intense
symptomatology and/or the tendency of a more dramatic
account of the state, a "hysterical" disposition. The lower
sensitivity of our proposed six-question screening battery
in the American versus in the Swedish subjects may be due
to a lower degree of symptomatology in the former, pre-
dominately reproductive-aged (mean 43 ± 9 years,
median = 41 years) relatives of patients versus in the our
older patients (mean 49 ± 9 years, median = 51 years, Stu-
dents t-test P = 0.021 for the mean age difference between
these groups) who themselves suffer from chronic mental
illness. Applying the American data in a highly-selected
population whereas 67% have some degree of energy
depletion (equal to that in our Swedish cohort), our data
corresponds to a 93% positive predictive value and a 72%
negative predictive value for the screening battery, with a
Table 1: Brief screening test developed from six selected items of the Karolinska Scales of Personality
KSP question answered by 
participants
KSP scale containing the 
question
KSP Item # Low vs. normal ATP 
production rate, 
Swedish subjects
Mitochondrial vs. 
control groups, 
American subjects
My heart sometimes beats hard or 
irregularly for no real reason.
Somatic Anxiety 34 10/14 vs. 0/7
P = 0.003
13/24 vs. 0/30
P = 3.7 × 10-6
I often have aches in my shoulders 
and in the back of my neck.
Muscular Tension 4 9/14 vs. 1/7
P = 0.031
12/24 vs. 1/30
P = 6.7 × 10-5
My body often feels stiff and tense. Muscular Tension 33 9/14 vs. 1/7
P = 0.031
5/24 vs. 0/30
P = 0.013
I think I must economize my 
energy.
Psychasthenia 40 8/14 vs. 0/7
P = 0.015
6/24 vs. 1/30
P = 0.025
In order to get something done I 
have to spend more energy than 
most others.
Psychasthenia 53 9/14 vs. 1/7
P = 0.031
6/24 vs. 1/30
P = 0.025
I feel easily pressured when I am 
urged to speed up.
Psychasthenia 93 10/14 vs. 1/7
P = 0.014
2/24 vs. 1/30 Non-significant
(P = 0.42)
The numbering of items refers to the 135-items KSP questionnaire. P-values refer to chi-square or Fisher exact test values in participants answering 
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positive response defined as 2 to 6 questions answered as
"Applies Completely". In a hypothetical population of
lesser acuity whereas only 10% have some degree of
energy depletion, our data corresponds to a 64% positive
predictive value and a 95% negative predictive value.
In the functional disorder of migraine, which demon-
strates strong co-morbidity with depression [16], co-
enzyme Q10 [17] and riboflavin [18], a component and a
precursor of a component of the mitochondrial respira-
tory chain, have shown efficacy in double-blind, placebo-
controlled clinical trials. Creatine, a source of stored
energy for brain, has recently been reported to be benefi-
cial in unipolar depression resistant to pharmacological
treatment [19]. These "mitochondrial-directed" therapies
have demonstrated efficacy in patients with mitochon-
drial disorders [20-22]. In our anecdotal observations
with the same therapies, and lipoic acid [20], improve-
ment in somatic symptomatology, and possibly in depres-
sion itself, was noted in over half of the depressed
subjects. The potential for effective therapy underscores
the need to screen depressed patients with somatic symp-
toms for those that might benefit from additional mito-
chondrial-related investigations (especially quantitative
urine organic acids while symptomatic) and/or therapies.
We propose that energy depletion constitutes at least part
of the inherited biological predisposition towards the
development of depression with somatization predicted
by Freud. Furthermore, although our present findings
require additional validation in varied groups of patients,
our preliminary data suggest that a small number of spe-
cific somatic-related questions, inquiring for symptoms
that likely would be instantly recognizable by Briquet and
Freud, can be constructed into a valid screening instru-
ment for cases at high risk for having a component of
energy metabolism in their pathogenesis, or "mito-
somatic" illness.
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